Basal Cell Nevus Syndrome (BCNS) – Pipeline Insight, 2020
This report can be delivered to the clients within 48-72 Hours
DelveInsight’s, “Basal Cell Nevus Syndrome (BCNS) – Pipeline Insight, 2020,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Basal Cell Nevus Syndrome (BCNS) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Basal Cell Nevus Syndrome (BCNS): Overview
Basal Cell Nevus Syndrome (BCNS) is a multisystemic autosomal dominant disorder with a high penetrance and variable expressiveness. BCNS is a rare inherited condition characterised by multiple and early onset basal cell carcinomas and other tumours including melanoma, medulloblastoma, meningioma, breast carcinoma, non-Hodgkin lymphoma, and ovarian fibroma. The other names for BCNS include basal cell carcinoma nevus syndrome (BCCNS), Gorlin-Goltz syndrome, Gorlin syndrome, and nevoid basal cell carcinoma syndrome. These basal cell naevi are actually tiny basal cell carcinomas. It is mostly caused by mutations in the PTCH1 gene, sometimes mutations in the SUFU and PTCH2 genes can cause a similar set of characteristics (phenotype).
Symptoms
The symptoms of Basal Cell Nevus Syndrome (BCNS) include:
A diagnosis of Basal Cell Nevus Syndrome (BCNS) is based upon physical examination, detection of a pathogenic genetic variant, identification of characteristic clinical findings and imaging studies. The physical examination include oral exploration, cephalic diameter, craniofacial morphology, skin exploration, and evaluation of the palms and soles. Complementary tests includes skull X-rays, orthopantogram, chest X-ray, and spinal X-ray. Ultrasound examinations are used to diagnose cardiac and ovarian fibromas. The diagnosis of BCNS can be confirmed by the detection of a mutation of the PTCH gene.
Treatment
Treating the underlying cause of Basal Cell Nevus Syndrome (BCNS) a multidisciplinary approach. The first-line of treatment for limited BCCs (nodular or aggressive) is usually surgical excision by standard or micro excisional/Mohs techniques. A wide variety of other treatment options for individuals with BCCs includes topical chemotherapy, drug therapy, cryotherapy, electrodessication and curettage, and photodynamic therapy. Future treatment options for BCNS patients include PTCH1- or SMO-specific targeted drugs which prevent the expression of tumor mediating genes within the hedgehog pathway.
Basal Cell Nevus Syndrome (BCNS) Emerging Drugs Chapters
This segment of the Basal Cell Nevus Syndrome (BCNS) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Basal Cell Nevus Syndrome (BCNS) Emerging Drugs
Further product details are provided in the report
Basal Cell Nevus Syndrome (BCNS): Therapeutic Assessment
This segment of the report provides insights about the different Basal Cell Nevus Syndrome (BCNS) drugs segregated based on following parameters that define the scope of the report, such as:
Basal Cell Nevus Syndrome (BCNS): Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Basal Cell Nevus Syndrome (BCNS) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Basal Cell Nevus Syndrome (BCNS) drugs.
Report Highlights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Basal Cell Nevus Syndrome (BCNS) – Pipeline Insight, 2020,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Basal Cell Nevus Syndrome (BCNS) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Basal Cell Nevus Syndrome (BCNS): Overview
Basal Cell Nevus Syndrome (BCNS) is a multisystemic autosomal dominant disorder with a high penetrance and variable expressiveness. BCNS is a rare inherited condition characterised by multiple and early onset basal cell carcinomas and other tumours including melanoma, medulloblastoma, meningioma, breast carcinoma, non-Hodgkin lymphoma, and ovarian fibroma. The other names for BCNS include basal cell carcinoma nevus syndrome (BCCNS), Gorlin-Goltz syndrome, Gorlin syndrome, and nevoid basal cell carcinoma syndrome. These basal cell naevi are actually tiny basal cell carcinomas. It is mostly caused by mutations in the PTCH1 gene, sometimes mutations in the SUFU and PTCH2 genes can cause a similar set of characteristics (phenotype).
Symptoms
The symptoms of Basal Cell Nevus Syndrome (BCNS) include:
- Multiple basal cell carcinomas
- Recurrent keratocystic odontogenic tumors of the jaws
- Skeletal malformations (some affected individuals may have distinctive facial features)
- Odontogenic cysts in the jaw
- Broad forehead
- Pits on palms and soles
- Rib anomalies
- Calcified falx cerebri (noted on skull X-ray)
A diagnosis of Basal Cell Nevus Syndrome (BCNS) is based upon physical examination, detection of a pathogenic genetic variant, identification of characteristic clinical findings and imaging studies. The physical examination include oral exploration, cephalic diameter, craniofacial morphology, skin exploration, and evaluation of the palms and soles. Complementary tests includes skull X-rays, orthopantogram, chest X-ray, and spinal X-ray. Ultrasound examinations are used to diagnose cardiac and ovarian fibromas. The diagnosis of BCNS can be confirmed by the detection of a mutation of the PTCH gene.
Treatment
Treating the underlying cause of Basal Cell Nevus Syndrome (BCNS) a multidisciplinary approach. The first-line of treatment for limited BCCs (nodular or aggressive) is usually surgical excision by standard or micro excisional/Mohs techniques. A wide variety of other treatment options for individuals with BCCs includes topical chemotherapy, drug therapy, cryotherapy, electrodessication and curettage, and photodynamic therapy. Future treatment options for BCNS patients include PTCH1- or SMO-specific targeted drugs which prevent the expression of tumor mediating genes within the hedgehog pathway.
Basal Cell Nevus Syndrome (BCNS) Emerging Drugs Chapters
This segment of the Basal Cell Nevus Syndrome (BCNS) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Basal Cell Nevus Syndrome (BCNS) Emerging Drugs
- Patidegib - PellePharm
- Vismodegib: Roche
Further product details are provided in the report
Basal Cell Nevus Syndrome (BCNS): Therapeutic Assessment
This segment of the report provides insights about the different Basal Cell Nevus Syndrome (BCNS) drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Basal Cell Nevus Syndrome (BCNS)
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Basal Cell Nevus Syndrome (BCNS): Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Basal Cell Nevus Syndrome (BCNS) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Basal Cell Nevus Syndrome (BCNS) drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Basal Cell Nevus Syndrome (BCNS) R&D. The therapies under development are focused on novel approaches to treat/improve Basal Cell Nevus Syndrome (BCNS).
- Basal Cell Nevus Syndrome (BCNS) Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Basal Cell Nevus Syndrome (BCNS) drugs?
- How many Basal Cell Nevus Syndrome (BCNS) drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Basal Cell Nevus Syndrome (BCNS)?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Basal Cell Nevus Syndrome (BCNS) therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Basal Cell Nevus Syndrome (BCNS) and their status?
- What are the key designations that have been granted to the emerging drugs?
- Palvella Therapeutics
- Sun Pharmaceutical Industries
- Roche
- PellePharm
- Asana BioSciences
- Mayne Pharma
- Sirolimus topical
- Sonidegib
- Vismodegib
- Patidegib
- Gusacitinib
- SUBA-Itraconazole
Introduction
Executive Summary
Basal Cell Nevus Syndrome (BCNS): Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Basal Cell Nevus Syndrome (BCNS) – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Basal Cell Nevus Syndrome (BCNS) companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Basal Cell Nevus Syndrome (BCNS) Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Patidegib - PellePharm
Product Description
Research and Development
Product Development Activities
Mid Stage Products (Phase II)
Comparative Analysis
Vismodegib - Roche
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
Sirolimus topical: Palvella Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Basal Cell Nevus Syndrome (BCNS) Key Companies
Basal Cell Nevus Syndrome (BCNS) Key Products
Basal Cell Nevus Syndrome (BCNS)- Unmet Needs
Basal Cell Nevus Syndrome (BCNS)- Market Drivers and Barriers
Basal Cell Nevus Syndrome (BCNS)- Future Perspectives and Conclusion
Basal Cell Nevus Syndrome (BCNS) Analyst Views
Basal Cell Nevus Syndrome (BCNS) Key Companies
Appendix
Executive Summary
Basal Cell Nevus Syndrome (BCNS): Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Basal Cell Nevus Syndrome (BCNS) – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Basal Cell Nevus Syndrome (BCNS) companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Basal Cell Nevus Syndrome (BCNS) Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Patidegib - PellePharm
Product Description
Research and Development
Product Development Activities
Mid Stage Products (Phase II)
Comparative Analysis
Vismodegib - Roche
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
Sirolimus topical: Palvella Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Basal Cell Nevus Syndrome (BCNS) Key Companies
Basal Cell Nevus Syndrome (BCNS) Key Products
Basal Cell Nevus Syndrome (BCNS)- Unmet Needs
Basal Cell Nevus Syndrome (BCNS)- Market Drivers and Barriers
Basal Cell Nevus Syndrome (BCNS)- Future Perspectives and Conclusion
Basal Cell Nevus Syndrome (BCNS) Analyst Views
Basal Cell Nevus Syndrome (BCNS) Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Basal Cell Nevus Syndrome (BCNS)
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Basal Cell Nevus Syndrome (BCNS)
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Basal Cell Nevus Syndrome (BCNS)
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Basal Cell Nevus Syndrome (BCNS)
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
